Chugai Pharmaceutical Co Ltd (CHGCY)
20.30
-0.39
(-1.88%)
USD |
OTCM |
Nov 22, 16:00
Chugai Pharmaceutical Revenue (Quarterly): 2.125B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.125B |
| June 30, 2024 | 2.027B |
| March 31, 2024 | 1.597B |
| December 31, 2023 | 1.854B |
| September 30, 2023 | 1.785B |
| June 30, 2023 | 1.949B |
| March 31, 2023 | 2.364B |
| December 31, 2022 | 3.110B |
| September 30, 2022 | 1.631B |
| June 30, 2022 | 1.818B |
| March 31, 2022 | 3.102B |
| December 31, 2021 | 2.835B |
| September 30, 2021 | 2.610B |
| June 30, 2021 | 2.023B |
| March 31, 2021 | 1.594B |
| December 31, 2020 | 2.015B |
| September 30, 2020 | 1.964B |
| June 30, 2020 | 1.754B |
| March 31, 2020 | 1.648B |
| December 31, 2019 | 1.631B |
| September 30, 2019 | 1.758B |
| June 30, 2019 | 1.510B |
| March 31, 2019 | 1.401B |
| December 31, 2018 | 1.360B |
| September 30, 2018 | 1.268B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.262B |
| March 31, 2018 | 1.360B |
| December 31, 2017 | 1.298B |
| September 30, 2017 | 1.216B |
| June 30, 2017 | 1.146B |
| March 31, 2017 | 1.103B |
| December 31, 2016 | 1.194B |
| September 30, 2016 | 1.114B |
| June 30, 2016 | 1.182B |
| March 31, 2016 | 1.041B |
| December 31, 2015 | 1.079B |
| September 30, 2015 | 1.044B |
| June 30, 2015 | 1.015B |
| March 31, 2015 | 982.66M |
| December 31, 2014 | 1.116B |
| September 30, 2014 | 1.072B |
| June 30, 2014 | 959.11M |
| March 31, 2014 | 1.206B |
| December 31, 2013 | 1.166B |
| September 30, 2013 | 1.067B |
| June 30, 2013 | 1.120B |
| March 31, 2013 | 981.79M |
| December 31, 2012 | 1.367B |
| September 30, 2012 | 1.146B |
| June 30, 2012 | 1.187B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.594B
Minimum
Mar 2021
3.110B
Maximum
Dec 2022
2.072B
Average
1.956B
Median
Revenue (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 7.918B |
| Nxera Pharma Co Ltd | 62.36M |
| PeptiDream Inc | 36.83M |
| Healios KK | 3.195M |
| AnGes Inc | 0.8352M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 737.17M |
| Total Expenses (Quarterly) | 1.045B |
| EPS Diluted (Quarterly) | 0.224 |
| Enterprise Value | 61.74B |
| Gross Profit Margin (Quarterly) | 73.32% |
| Profit Margin (Quarterly) | 34.69% |
| Earnings Yield | 3.85% |
| Operating Earnings Yield | 5.35% |
| Normalized Earnings Yield | 3.852 |